Concalls & earnings callsGufic Biosciences Limited

Every summarised call, newest first. Latest is Q1 FY27, held 17 Aug 2026.

Latest quarter

Q1 FY27 snapshot

Gufic Biosciences delivered strong Q1 growth driven by improved margins from its new Indore plant, progress on complex injectable capabilities, and a strategic shift in its international business model.

Metric	This quarter	Change
Total Revenue from Operations	₹260.8 Cr	vs ₹226.9 Cr YoY
EBITDA	₹47.2 Cr	vs ₹33.2 Cr YoY
EBITDA Margin	18.09%	vs 14.6% YoY
Profit After Tax	₹22.46 Cr	vs ₹12.1 Cr YoY

Latest guidance

Target 15-20% year-on-year revenue growth as a minimum.
Indore capacity utilization to reach 40-45% by year-end.
EU certification for Indore expected in the next 1-2 months.
GLP-1 CMO operations to gain traction in Q2 and Q3.
Filler product launch expected by December 2026 or January 2027.
International B2C model to be rolled out in key emerging markets.

Said on the Q1 FY27 call.

Filed results

Reported quarterly history

From filed quarterly results. YoY and QoQ compare each metric on the same accounting basis.

Quarter	Revenue	Net profit (PAT)	Basic EPS
Q3 FY25	₹207.79 Cr+3% YoY+1.8% QoQ	₹19.31 Cr-13.3% YoY-11.3% QoQ	₹1.93-13.5% YoY-11.1% QoQ
Q2 FY25	₹204.18 Cr-5% YoY+0.7% QoQ	₹21.77 Cr-6.2% YoY+4.4% QoQ	₹2.17-9.2% YoY+4.3% QoQ
Q1 FY25	₹202.81 Cr— YoY+4% QoQ	₹20.86 Cr— YoY+4% QoQ	₹2.08— YoY+4% QoQ
Q4 FY24	₹194.99 Cr— YoY-3.4% QoQ	₹20.05 Cr— YoY-9.9% QoQ	₹2.00— YoY-10.3% QoQ
Q3 FY24	₹201.78 Cr— YoY-6.1% QoQ	₹22.26 Cr— YoY-4.1% QoQ	₹2.23— YoY-6.7% QoQ

Call history

17 Aug 2026
Q1 FY27Positive tone
Gufic Biosciences delivered strong Q1 growth driven by improved margins from its new Indore plant, progress on complex injectable capabilities, and a strategic shift in its international business model.
Total Revenue from Operations
₹260.8 Crvs ₹226.9 Cr YoY
EBITDA
₹47.2 Crvs ₹33.2 Cr YoY
Pharmaceuticals & HealthcareVerified brief6 guidance items